Bioavailable copper complexes offer a physiologic approach to treatment of chronic diseases.
Copper (II)2(3,5-Diisopropylsalicylate)4(H2O)2 has been found to have antiinflammatory, antiulcer, anticonvulsant, anticancer, anticarcinogenic, antimutagenic, and radiation recovery activities and it prevents reperfusion injury. To study pharmacokinetic parameters accounting for these pharmacological effects the double labeled 67Cu(II)2(carboxy-14C-3,5-diisopropylsalicylate)4 complex was synthesized and used to obtain these parameters. Treatment of mice with 1 mumol of this complex revealed that 67Cu was distributed to blood, liver, kidney, intestine, lung, thymus, femur, muscle, spleen, brain, urine, and feces within 0.5 hr and patterned changes in 67Cu content of these tissues and excreta were found throughout the 96 hr term of this study.
Sorenson
J R
JR
Division of Medicinal Chemistry, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock 72205.
Soderberg
L S
LS
Chidambaram
M V
MV
de la Rosa
D T
DT
Salari
H
H
Bond
K
K
Kearns
G L
GL
Gray
R A
RA
Epperson
C E
CE
Baker
M L
ML
D000818:Animals; D001682:Biological Availability; D055598:Chemical Phenomena; D002621:Chemistry; D002908:Chronic Disease; D003300:Copper / Q000493:pharmacokinetics / Q000627:therapeutic use*; D051379:Mice; D009928:Organ Specificity; D012459:Salicylates / Q000493:pharmacokinetics
D012459:Salicylates; C030865:copper bis(3,5-diisopropylsalicylate); D003300:Copper